EMERYVILLE, California, June 9, 2016 /PRNewswire/ -- Trianni, Inc. is pleased to announce that a patent for the Trianni Mouse Platform was issued by the Chinese State Intellectual Property Office. The Trianni Mouse Platform is a human monoclonal antibody discovery platform based on a novel chimeric gene segment design, and featuring extensive variable domain diversity. It provides a complete human antibody repertoire for the isolation of fully human therapeutics.
"The issuance of this patent in China will provide intellectual property protection of the Trianni Mouse Platform in an emerging market with immense growth potential," remarked Dr. Matthias Wabl, Ph.D., Chairman and CEO of Trianni. "It recognizes the novelty of the approach that Trianni used to generate the platform. Rather than cloning DNA fragments from the human genome, Trianni used chemically synthesized large DNA segments with sequences that do not exist in nature. Designed in silico, these segments are modified versions of the mouse immunoglobulin loci, with human exons embedded in mouse control regions and intergenic DNA."
About Trianni, Inc.
Trianni is a privately held organization, formed in 2010 with a mission to enterprise recent advances in DNA synthesis and genomic modification technology for the development of an optimized therapeutic antibody discovery platform, The Trianni Mouse. The company has research and administrative facilities in the San Francisco Bay Area (California, USA) and in Research Triangle Park (North Carolina, USA). For more information, please visit www.trianni.com.
Contacts
Zishan Haroon, MD, PhD
Chief Business Officer
1.415.231.0257 [o]
drz@trianni.com
Mandy Boyd
Director of Marketing
1.415.231.0256 [o]
1.866.674.9314
mandy.boyd@trianni.com